JCR initiates clinical trial of JR-142, a long-acting growth hormone
TOKYO: JCR Pharmaceuticals Co., Ltd. has initiated Phase 1 clinical trial of JR-142, a recombinant long-acting growth hormone. JCR is developing JR-142 to further upgrade and enhance its growth hormone…